6-месячное и 18-месячное рандомизированное двойное исследование по оценке безопасности и эффективности бунтанетапа у участников с ранней AD (DUET-AD)
6-месячное и 18-месячное проспективное рандомизированное плацебо-контролируемое двойное слепое двойное клиническое исследование по изучению эффективности и безопасности бунтанетапа при лечении участников с ранней болезнью Альцгеймера.
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:
- Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
- Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
- What medical issues do participants have, if any, when taking buntanetap/Posiphen?
Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.
Participants will:
- Take buntanetap/Posiphen or a placebo every day for 18 months
- Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
- Complete pre- and post-clinic visit phone calls
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Тип исследования
Тип исследования
Регистрация (Действительный)
Регистрация
Фаза
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
Arizona
-
Chandler, Arizona, Соединенные Штаты, 85286
- MD First Research
-
Phoenix, Arizona, Соединенные Штаты, 85004
- Xenoscience
-
Scottsdale, Arizona, Соединенные Штаты, 85258
- Clinical Endpoints
-
-
California
-
Anaheim, California, Соединенные Штаты, 92805
- Advanced Research Center
-
Canoga Park, California, Соединенные Штаты, 91303
- Hope Clinical Research
-
Imperial, California, Соединенные Штаты, 92251
- Sun Valley Research
-
Los Angeles, California, Соединенные Штаты, 90095
- Mary S. Easton Center for Alzheimer's Research and Care, UCLA
-
Sacramento, California, Соединенные Штаты, 95816
- UC Davis Alzheimer's Disease Research Center
-
San Marcos, California, Соединенные Штаты, 92069
- The Neuron Clinic
-
-
Colorado
-
Basalt, Colorado, Соединенные Штаты, 81621
- Mountain Neurological Center
-
Englewood, Colorado, Соединенные Штаты, 80113
- CenExel Rocky Mountain
-
-
Connecticut
-
Norwalk, Connecticut, Соединенные Штаты, 06851
- Research Center for Clinical Trials
-
-
Florida
-
Aventura, Florida, Соединенные Штаты, 33180
- Visionary Investigators Network
-
Boca Raton, Florida, Соединенные Штаты, 33487
- SFM Clinical Research
-
Clermont, Florida, Соединенные Штаты, 34711
- K2 Medical Research
-
Daytona Beach, Florida, Соединенные Штаты, 32114
- K2 Medical Research Daytona
-
Fort Myers, Florida, Соединенные Штаты, 33912
- Neuropsychiatric Research Center
-
Hallandale, Florida, Соединенные Штаты, 33009
- Velocity Clinical
-
Jacksonville, Florida, Соединенные Штаты, 32216
- Jacksonville Center for Clinical Research
-
Lady Lake, Florida, Соединенные Штаты, 32159
- K2 Medical Research
-
Lake Worth, Florida, Соединенные Штаты, 33462
- Headlands Research JEM
-
Lakeland, Florida, Соединенные Штаты, 33803
- Accel Research Sites Lakeland (Alcanza)
-
Maitland, Florida, Соединенные Штаты, 32751
- K2 Medical Research
-
Melbourne, Florida, Соединенные Штаты, 32940
- ClinCloud Clinical Research
-
Merritt Island, Florida, Соединенные Штаты, 32952
- Flourish Research/Merritt Island Medical Research
-
Miami, Florida, Соединенные Штаты, 33137
- Miami Jewish Health
-
Naples, Florida, Соединенные Штаты, 34102
- Aqualane Clinical Research
-
New Port Richey, Florida, Соединенные Штаты, 34652
- Suncoast Clinical Research
-
Orlando, Florida, Соединенные Штаты, 32832
- Conquest Research
-
Tampa, Florida, Соединенные Штаты, 33609
- Axiom Brain Health, LLC
-
Winter Park, Florida, Соединенные Штаты, 32789
- Conquest Research
-
-
Georgia
-
Decatur, Georgia, Соединенные Штаты, 30030
- Accel Neurosciences
-
Gainesville, Georgia, Соединенные Штаты, 30501
- CARE (Center for Advanced Research & Education)
-
-
Hawaii
-
Honolulu, Hawaii, Соединенные Штаты, 96817
- Hawaii Pacific Neuroscience
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60612
- Rush University Medical Center
-
Chicago, Illinois, Соединенные Штаты, 60611
- Re:Cognition Chicago
-
Chicago, Illinois, Соединенные Штаты, 60618
- Charter Research Chicago
-
Chicago, Illinois, Соединенные Штаты, 60640
- Great Lakes Clinical Trials/Flourish Research
-
Springfield, Illinois, Соединенные Штаты, 62702
- Southern Illinois University
-
-
Indiana
-
Indianaopolis, Indiana, Соединенные Штаты, 46256
- JWM Research
-
-
Kansas
-
Wichita, Kansas, Соединенные Штаты, 37214
- Ascension via Christi Research
-
-
Louisiana
-
Metairie, Louisiana, Соединенные Штаты, 70006
- Tandem Intermediate
-
-
Maryland
-
Pikesville, Maryland, Соединенные Штаты, 21208
- Headlands Research Pharmasite
-
-
Massachusetts
-
Foxborough, Massachusetts, Соединенные Штаты, 02035
- Neurology Center of New England, PC
-
Plymouth, Massachusetts, Соединенные Штаты, 02360
- Headlands Research Easter Massachusetts
-
Russells Mills, Massachusetts, Соединенные Штаты, 02747
- Mayflower Clinical
-
Springfield, Massachusetts, Соединенные Штаты, 01103
- Elixia MA
-
-
Michigan
-
Farmington Hills, Michigan, Соединенные Штаты, 48334
- Quest Research Institute
-
-
Mississippi
-
Flowood, Mississippi, Соединенные Штаты, 39232
- Precise Research Center
-
-
Missouri
-
Chesterfield, Missouri, Соединенные Штаты, 63005
- Clinical Research Professionals - Headlands Research
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты, 89121
- Oasis Clinical Trials LLC
-
-
New Jersey
-
Toms River, New Jersey, Соединенные Штаты, 08755
- Cenexel Advanced Medical Research of New Jersey (AMRI)
-
West Long Branch, New Jersey, Соединенные Штаты, 07764
- Advanced Clinical Institute
-
-
New York
-
Amherst, New York, Соединенные Штаты, 14226
- Dent Neurologic Institute
-
Brooklyn, New York, Соединенные Штаты, 11235
- SPRI
-
Lake Success, New York, Соединенные Штаты, 11042
- Neurological Associates of Long Island
-
New York, New York, Соединенные Штаты, 10003
- New York Neurology Associates
-
Staten Island, New York, Соединенные Штаты, 10314
- Richmond Behavioral Associates
-
Syracuse, New York, Соединенные Штаты, 13210
- Ichor Research
-
-
North Carolina
-
Durham, North Carolina, Соединенные Штаты, 27705
- Duke University
-
Matthews, North Carolina, Соединенные Штаты, 28105
- AMC Research/Flourish Research
-
-
Ohio
-
Beavercreek, Ohio, Соединенные Штаты, 45432
- American Clinical Research Center
-
Centerville, Ohio, Соединенные Штаты, 45459
- Valley Medical Research
-
Independence, Ohio, Соединенные Штаты, 44131
- Insight Clinical Trials
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97210
- Summit Headlands
-
-
Pennsylvania
-
Media, Pennsylvania, Соединенные Штаты, 19063
- Suburban Research Associates
-
Plymouth Meeting, Pennsylvania, Соединенные Штаты, 19462
- K2 Keystone
-
-
Rhode Island
-
East Providence, Rhode Island, Соединенные Штаты, 02914
- Rhode Island Mood and Memory Research Institute
-
-
South Carolina
-
Summerville, South Carolina, Соединенные Штаты, 29486
- Palmetto Primary Care & Specialty Physicians
-
-
Tennessee
-
Cordova, Tennessee, Соединенные Штаты, 38018
- Neurology Clinic, P.C.
-
Nashville, Tennessee, Соединенные Штаты, 37204
- K2 Medical Research Nashville
-
-
Texas
-
Austin, Texas, Соединенные Штаты, 78757
- Senior Adults Specialty Research
-
Houston, Texas, Соединенные Штаты, 77094
- NeuroMind Clinical Trials
-
Round Rock, Texas, Соединенные Штаты, 78681
- Central Texas Neurology Associates
-
Wichita Falls, Texas, Соединенные Штаты, 76309
- Grayline Research Center
-
-
Vermont
-
Bennington, Vermont, Соединенные Штаты, 05201
- Memory Clinic, Inc.
-
-
Virginia
-
Arlington, Virginia, Соединенные Штаты, 22205
- Sana Research
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Re:Cognition Fairfax
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.
-
Male or female, aged 55 - 85 years.
-
MMSE 20-28 at screening and baseline.
-
CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.
-
Positive for amyloid beta as defined by plasma p-tau217 level at screening.
-
Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.
-
Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.
-
Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:
-
Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
-
Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
-
Intrauterine device (IUD),
-
Intrauterine hormone-releasing system (IUS),
-
Bilateral tubal occlusion,
-
Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),
-
Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).
- Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
-
-
Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:
- Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
- Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
- IUD,
- IUS,
- Bilateral tubal occlusion.
-
General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.
-
No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
-
Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.
- Cholinesterase inhibitors and/or memantine medication,
- Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
- Mood-stabilizing psychotropic agents including, but not limited to, lithium.
-
Adequate visual and hearing ability (physical ability to perform all the study assessments).
-
Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.
Exclusion Criteria:
-
Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.
-
History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).
-
Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.
-
Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.
-
Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.
-
Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).
-
Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.
-
Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
-
Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
-
Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
-
Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
-
Participants with learning disability or developmental delay.
-
Participants whom the PI deems to be otherwise ineligible.
-
Participants with a known allergy to the investigational drug or any of its components.
Inactive ingredients of the investigational medicinal product:
- Silicified Microcrystalline Cellulose
- Dibasic Calcium Phosphate Dihydrate
- Mannitol
- Stearic Acid
- Hypromellosee (capsule shells structure)
- Titanium dioxide (opacifier of the capsule shells)
-
Participant is currently pregnant, breast-feeding, and/or lactating.
-
Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.
-
Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Плацебо Компаратор: Плацебо
|
Placebo capsule by mouth once daily for 18 months |
|
Экспериментальный: бантанетап
|
30mg capsule by mouth once daily for 18 months |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Временное ограничение: From screening to 6-month readout, to end of treatment at 18 months.
|
ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment. |
From screening to 6-month readout, to end of treatment at 18 months.
|
|
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Временное ограничение: From screening to 6-month readout, to end of treatment at 18 months.
|
The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function. |
From screening to 6-month readout, to end of treatment at 18 months.
|
Соавторы и исследователи
Спонсор
Спонсор
Соавторы
Соавторы
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- ANVS-25001
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .